ArticleOphthalmology2021
Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study.
Article in Ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review.Eye (London, England) · 2023Pooled it
- Ranibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Tracer Techniques in Ophthalmology: Ocular Applications and Systemic Connections.Diagnostics (Basel, Switzerland) · 2026Review
- Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2.Eye (London, England) · 2026Observational
- Standardization of Imaging Criteria for Detecting Macular Fibrosis in Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- The Amsler Grid in Everyday Practice: A Review of Its Role and Limitations in Primary Care.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Comparison of 1-year outcomes after switching to faricimab in neovascular age-related macular degeneration previously treated with anti-VEGF agents with/without a loading phase.Japanese journal of ophthalmology · 2026Article
- Article
- Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey.Medicina (Kaunas, Lithuania) · 2025Review
- Morphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration.International ophthalmology · 2025Article
- Updates on novel and traditional OCT and OCTA biomarkers in nAMD.Eye (London, England) · 2025Review
- Prevalence and risk factors of undiagnosed age-related macular degeneration: the Korea National Health and Nutrition Examination Survey 2017-2020.Scientific reports · 2025Article
- Remote web-based self-assessment of visual acuity versus ETDRS in patients with macular diseases: a method comparison study.International journal of retina and vitreous · 2025Article
- Age-Related Macular Degeneration: A Review.JAMA · 2024Review
- Assessing Change in Exudative Age-Related Macular Degeneration With Macular Thickness Maps as a Surrogate Strategy for Remote Patient Monitoring.American journal of ophthalmology · 2023Article
- Telehealth improves follow-up and monitoring of age-related macular degeneration during the COVID-19 pandemic.International ophthalmology · 2023Article
- Correlation of Aqueous, Vitreous, and Serum Protein Levels in Patients With Retinal Diseases.Translational vision science & technology · 2023Article
- Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes.BMC ophthalmology · 2023Article
- Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD.Eye (London, England) · 2023Article
- Prognostic Optical Coherence Tomography Biomarkers in Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2023Review
Corrections and comments
- Erratum issuedCorrigendum.2025
Authors and funding
18 authors at 13 institutions in 1 country.
Funding
Abstract
purposeTo evaluate the diagnostic accuracy of routinely used tests of visual function and retinal morphology compared with fundus fluorescein angiography (FFA) to detect onset of active macular neovascularization in unaffected fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD).
designProspective diagnostic accuracy cohort study conducted in 24 eye clinics in the United Kingdom over 3 years.
participantsOlder adults (>50 years) with recently diagnosed unilateral nAMD with a fellow (study) eye free of nAMD.
methodsSelf-reported vision, Amsler, clinic-measured visual acuity (VA), fundus assessment, and spectral domain OCT. The reference standard is FFA.
main outcome measuresSensitivity and specificity of the 5 index tests.
resultsOf 552 participants monitored for up to 3 years, 145 (26.3%) developed active nAMD in the study eye, of whom 120 had an FFA at detection and constituted the primary analysis cohort. Index test positives at nAMD detection in those confirmed by FFA were self-reported vision much worse (5), distortion on Amsler (33), 10-letter decrease in acuity from baseline (36), fundus examination (64), and OCT (110). Percentage index test sensitivities were: self-reported vision 4.2 (95% confidence interval [CI], 1.6-9.8); Amsler 33.7 (95% CI, 25.1-43.5); VA 30.0 (95% CI, 22.5-38.7); fundus examination 53.8 (95% CI, 44.8-62.5); and OCT 91.7 (95% CI, 85.2-95.6). All 5 index test specificities were high at 97.0 (95% CI, 94.6-98.5), 81.4 (95% CI, 76.4-85.5), 66.3 (95% CI, 61.0-71.1), 97.6 (95% CI, 95.3-98.9), and 87.8 (95% CI, 83.8-90.9), respectively. The combination of OCT with one other index test that was a secondary outcome measure increased sensitivity marginally and decreased specificity for all combinations except fundus examination.
conclusionsTests of self-reported change in vision, unmasking of new distortion, measurements of acuity, and fundus checks to diagnose active nAMD performed poorly in contrast to OCT. Our findings support a change to guidelines in clinical practice to monitor for onset of nAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.